These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8067000)

  • 1. [The characteristics of the antibiotic therapy of acute dysentery in an immunodeficiency body state in children with leukopenia].
    Vereshchagin IA; Zhuravleva OD
    Lik Sprava; 1994 Jan; (1):103-7. PubMed ID: 8067000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enhanced effectiveness of antibiotic therapy with an exogenous lysozyme in dysentery in children].
    Vereshchagin IA; Vereshchagin SI; Zhuravleva OD
    Antibiot Med Biotekhnol; 1985 Dec; 30(12):927-31. PubMed ID: 3936408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibiotic therapy of acute dysentery in children with immunologic deficiency conditions].
    Vereshchagin IA; Zhuravleva OD
    Antibiot Khimioter; 1991 Jan; 36(1):38-41. PubMed ID: 2053823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of prodigiozan for increasing the effectiveness of the antibiotic therapy of dysentery in children].
    Vereshchagin IA; Zhuravleva OD
    Antibiotiki; 1984 Oct; 29(10):791-4. PubMed ID: 6439109
    [No Abstract]   [Full Text] [Related]  

  • 5. [Increased effectiveness of antibiotic therapy with adaptogens in dysentery and Proteus infection in children].
    Vereshchagin IA; Geskina OD; Bukhteeva ER
    Antibiotiki; 1982 Jan; 27(1):65-9. PubMed ID: 7036851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of determining the spectrum of blood serum fatty acids in evaluating increasing the effectiveness of antibiotic therapy of dysentery in children with prodigiozan and ephedrine].
    Vereshchagin IA; Zhuravleva OD
    Antibiot Khimioter; 1989 Mar; 34(3):218-23. PubMed ID: 2502081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Various approaches to treatment of dysentery in children].
    Iushkevich SB; Pozniak SB; Pivovarchik RA
    Antibiot Khimioter; 1993; 38(4-5):40-2. PubMed ID: 8031196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of a secondary immunodeficiency in the pathogenesis of different forms of dysentery].
    Usychenko EM; Mashilov VP
    Ter Arkh; 1991; 63(11):18-9. PubMed ID: 1810052
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative effectiveness of the treatment of acute dysentery].
    Lyskovtsev MM; Myshkina OK; Romanova IG; Levicheva VS
    Klin Med (Mosk); 1979 Aug; 57(8):74-7. PubMed ID: 388065
    [No Abstract]   [Full Text] [Related]  

  • 10. [The importance of secondary immune deficiencies in the pathogenesis of dysentery].
    Mashilov VP; Usychenko EM
    Ter Arkh; 1988; 60(11):63-4. PubMed ID: 3070808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The immunocorrective therapy of patients with acute dysentery].
    Usychenko EM; Mashilov VP
    Lik Sprava; 1992 Jun; (6):125-6. PubMed ID: 1455821
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prodigiosin in the overall therapy of dysentery and in the prevention of intrahospital viral respiratory infection in children].
    Zlatkovskaia NM; Kleĭmenova IS; Evdoshenko VG; Zelenaia SN; Fuger NM
    Antibiotiki; 1975 Apr; 20(4):365-9. PubMed ID: 1108774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Importance of cellular and humoral immunity factors in dysentery in children].
    Tartakovskaia RA
    Vopr Okhr Materin Det; 1976 Nov; 21(11):43-5. PubMed ID: 795153
    [No Abstract]   [Full Text] [Related]  

  • 14. [Free amino acid content in the blood and urine from the use of monomycin on children with dysentery].
    Vereshchagin IA
    Antibiotiki; 1976 Aug; 21(8):754-8. PubMed ID: 793513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oral vaccination using live, apathogenic nondependent Shigella organisms].
    Meitert T; Istrati G; Ciufecu C; Sulea IT
    Z Gesamte Hyg; 1972 Oct; 18(10):753-6. PubMed ID: 4581672
    [No Abstract]   [Full Text] [Related]  

  • 16. [The role of secondary immunodeficiencies in the development of a protracted course of acute dysentery].
    Usychenko EM; Mashilov VP
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (2):111-3. PubMed ID: 8059562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current state of dysentery epidemiology (review of the literature)].
    Popovich GG; Bondarenko VI
    Vrach Delo; 1983 Jul; (7):94-9. PubMed ID: 6353765
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevention of bacillary dysentery using a live anti-dysentery vaccine in a group of neuropsychopathic children].
    Meitert T; Istrati G; Sulea IT; Baron E; Andronescu C; Gogulescu L; Templea C; Ianopol L; Galan L; Fleşeriu M; Onciu C; Bogos L; Lupovici R; Boghiţoiu G; Ohmt E; Popescu G; Mihailiuc I; Maftei S; Tapu T; Zebreniuc D
    Arch Roum Pathol Exp Microbiol; 1973 Mar; 32(1):35-44. PubMed ID: 4585403
    [No Abstract]   [Full Text] [Related]  

  • 19. [The efficacy of quercetin and tocopherol acetate in treating patients with Flexner's dysentery].
    Frolov VM; Peresadin NA; Khomutianskaia NI; Pshenichnyĭ IIa
    Lik Sprava; 1993 Apr; (4):84-6. PubMed ID: 8209460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [State of immunogenesis in different methods of treating acute dysentery].
    Chernaia TT; Beĭsembaev EA
    Klin Med (Mosk); 1980 Feb; 58(2):31-4. PubMed ID: 6988643
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.